UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Clifton EAD
(2018)
Genome-wide association study for risk taking propensity indicates shared pathways with body mass index.
in Communications biology
Clifton L
(2022)
Assessing agreement between different polygenic risk scores in the UK Biobank.
in Scientific reports
Climans S
(2022)
Glioma misclassification in "A prospective study of inflammatory biomarkers and growth factors and risk of glioma in the UK Biobank".
in Cancer epidemiology
Clough JR
(2022)
A Topological Loss Function for Deep-Learning Based Image Segmentation Using Persistent Homology.
in IEEE transactions on pattern analysis and machine intelligence
Clynes MA
(2019)
Impact of Rheumatoid Arthritis and Its Management on Falls, Fracture and Bone Mineral Density in UK Biobank.
in Frontiers in endocrinology
Codd V
(2021)
Polygenic basis and biomedical consequences of telomere length variation.
in Nature genetics
Cohen JB
(2022)
Arterial Stiffness and Diabetes Risk in Framingham Heart Study and UK Biobank.
in Circulation research
Cole JB
(2022)
Genetic heritability as a tool to evaluate the precision of 24-hour recall dietary questionnaire variables in UK Biobank.
in Frontiers in genetics
Cole JB
(2020)
Comprehensive genomic analysis of dietary habits in UK Biobank identifies hundreds of genetic associations.
in Nature communications
Cole JH
(2020)
Multimodality neuroimaging brain-age in UK biobank: relationship to biomedical, lifestyle, and cognitive factors.
in Neurobiology of aging
Coleman JRI
(2020)
Genome-wide gene-environment analyses of major depressive disorder and reported lifetime traumatic experiences in UK Biobank.
in Molecular psychiatry
Colodro-Conde L
(2018)
Association Between Population Density and Genetic Risk for Schizophrenia.
in JAMA psychiatry
Conley A
(2022)
Rye: genetic ancestry inference at biobank scale
Connally NJ
(2022)
The missing link between genetic association and regulatory function.
in eLife
Conroy MC
(2023)
UK Biobank: a globally important resource for cancer research.
in British journal of cancer
Constantinescu AE
(2022)
A framework for research into continental ancestry groups of the UK Biobank.
in Human genomics
Cook MJ
(2022)
Increased Frailty in Individuals With Osteoarthritis and Rheumatoid Arthritis and the Influence of Comorbidity: An Analysis of the UK Biobank Cohort.
in Arthritis care & research
Cook MJ
(2018)
The prevalence of co-morbidities and their impact on physical activity in people with inflammatory rheumatic diseases compared with the general population: results from the UK Biobank.
in Rheumatology (Oxford, England)
Cook W
(2019)
The effect of personalised weight feedback on weight loss and health behaviours: Evidence from a regression discontinuity design.
in Health economics
Corcoran NM
(2022)
Long-term conditions, multimorbidity and colorectal cancer risk in the UK Biobank cohort.
in Journal of multimorbidity and comorbidity
Corley E
(2021)
Microglial-expressed genetic risk variants, cognitive function and brain volume in patients with schizophrenia and healthy controls.
in Translational psychiatry
Cornelis M
(2020)
Recent Caffeine Drinking Associates with Cognitive Function in the UK Biobank
in Nutrients
Cornelis MC
(2021)
Recent consumption of a caffeine-containing beverage and serum biomarkers of cardiometabolic function in the UK Biobank.
in The British journal of nutrition
Cornelis MC
(2022)
Caffeine Consumption and Dementia: Are Lewy Bodies the Link?
in Annals of neurology
Cornelis MC
(2020)
Caffeinated Coffee and Tea Consumption, Genetic Variation and Cognitive Function in the UK Biobank.
in The Journal of nutrition
Cornelis MC
(2022)
MIND Dietary Pattern and Its Association with Cognition and Incident Dementia in the UK Biobank.
in Nutrients
Cortes A
(2020)
Identifying cross-disease components of genetic risk across hospital data in the UK Biobank.
in Nature genetics
Costantino M
(2022)
Menopause, Brain Anatomy, Cognition and Alzheimer's Disease
Cote DJ
(2021)
A prospective study of inflammatory biomarkers and growth factors and risk of glioma in the UK Biobank.
in Cancer epidemiology
Cote DJ
(2021)
Circulating lipids and glioma risk: results from the UK Biobank, Nurses' Health Study, and Health Professionals Follow-Up Study.
in Cancer causes & control : CCC
Couvy-Duchesne B
(2020)
A unified framework for association and prediction from vertex-wise grey-matter structure.
in Human brain mapping
Couvy-Duchesne B
(2022)
Parsimonious model for mass-univariate vertexwise analysis.
in Journal of medical imaging (Bellingham, Wash.)
Cox J
(2022)
AB0060 SYSTEMIC INFLAMMATORY EFFECT ON HIPPOCAMPAL VOLUME IN RHEUMATOID ARTHRITIS AND ULCERATIVE COLITIS
in Annals of the Rheumatic Diseases
Cox SR
(2019)
Structural brain imaging correlates of general intelligence in UK Biobank.
in Intelligence
Craig JE
(2020)
Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression.
in Nature genetics
Crawford K
(2019)
Medical consequences of pathogenic CNVs in adults: analysis of the UK Biobank.
in Journal of medical genetics
Creed JH
(2020)
A prospective study of coffee and tea consumption and the risk of glioma in the UK Biobank.
in European journal of cancer (Oxford, England : 1990)
Creed JH
(2019)
Methylmercury exposure, genetic variation in metabolic enzymes, and the risk of glioma.
in Scientific reports
Cresswell M
(2022)
Understanding Factors That Cause Tinnitus: A Mendelian Randomization Study in the UK Biobank.
in Ear and hearing
Croall I
(2020)
Cognitive Deficit and White Matter Changes in Persons With Celiac Disease: A Population-Based Study
in Gastroenterology
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |